Skip to Content
Merck
  • Epigenetic silencing of IRF1 dysregulates type III interferon responses to respiratory virus infection in epithelial to mesenchymal transition.

Epigenetic silencing of IRF1 dysregulates type III interferon responses to respiratory virus infection in epithelial to mesenchymal transition.

Nature microbiology (2017-06-06)
Jun Yang, Bing Tian, Hong Sun, Roberto P Garofalo, Allan R Brasier
ABSTRACT

Chronic oxidative injury produced by airway disease triggers a transforming growth factor-β (TGF-β)-mediated epigenetic reprogramming known as the epithelial-mesenchymal transition (EMT). We observe that EMT silences protective mucosal interferon (IFN)-I and III production associated with enhanced rhinovirus (RV) and respiratory syncytial virus (RSV) replication. Mesenchymal transitioned cells are defective in inducible interferon regulatory factor 1 (IRF1) expression by occluding RelA and IRF3 access to the promoter. IRF1 is necessary for the expression of type III IFNs (IFNLs 1 and 2/3). Induced by the EMT, zinc finger E-box binding homeobox 1 (ZEB1) binds and silences IRF1. Ectopic ZEB1 is sufficient for IRF1 silencing, whereas ZEB1 knockdown partially restores IRF1-IFNL upregulation. ZEB1 silences IRF1 through the catalytic activity of the enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), forming repressive H3K27(me3) marks. We observe that IRF1 expression is mediated by ZEB1 de-repression, and our study demonstrates how airway remodelling/fibrosis is associated with a defective mucosal antiviral response through ZEB1-initiated epigenetic silencing.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Di(N-succinimidyl) glutarate, ≥97.0% (CHN)
Sigma-Aldrich
Anti-Lamin B2 Antibody, clone LN43, clone LN43, Chemicon®, from mouse
Sigma-Aldrich
ChIPAb+ EZH2, clone AC22 - ChIP Validated Antibody and Primer Set, clone AC22, from mouse